Literature DB >> 26325033

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

Stefano Ugel, Francesco De Sanctis, Susanna Mandruzzato, Vincenzo Bronte.   

Abstract

The generation of an inflammatory environment is favorable and often decisive for the growth of both primary tumors and metastases. Tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis. Tumor-reprogrammed myeloid cells not only create a tolerogenic environment by blocking T cell functions and proliferation, but also directly drive tumor growth by promoting cancer stemness, angiogenesis, stroma deposition, epithelial-to-mesenchymal transition, and metastasis formation. In this Review, we discuss the interplay between immunosuppressive and protumoral myeloid cells and detail their immune-regulatory mechanisms, the molecular pathways involved in their differentiation, as well as their potential role as prognostic and diagnostic biomarkers and prospective targets for innovative approaches to treat tumor-bearing hosts.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26325033      PMCID: PMC4588310          DOI: 10.1172/JCI80006

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  161 in total

1.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.

Authors:  P'ng Loke; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

Review 2.  Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

Authors:  Alberto J Montero; Claudia Marcela Diaz-Montero; Christos E Kyriakopoulos; Vincenzo Bronte; Susanna Mandruzzato
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

3.  Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition.

Authors:  Dingcheng Gao; Natasha Joshi; Hyejin Choi; Seongho Ryu; Mary Hahn; Raul Catena; Helen Sadik; Pedram Argani; Patrick Wagner; Linda T Vahdat; Jeffrey L Port; Brendon Stiles; Saraswati Sukumar; Nasser K Altorki; Shahin Rafii; Vivek Mittal
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

Review 4.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

5.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

6.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients.

Authors:  Peng Shen; Aijuan Wang; Mengye He; Qingqing Wang; Shusen Zheng
Journal:  Hepatol Res       Date:  2013-07-10       Impact factor: 4.288

8.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

9.  Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.

Authors:  Minu K Srivastava; Jacobus J Bosch; James A Thompson; Bruce R Ksander; Martin J Edelman; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2008-03-06       Impact factor: 6.968

10.  Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Authors:  Ahmad A Tarhini; Howard Edington; Lisa H Butterfield; Yan Lin; Yongli Shuai; Hussein Tawbi; Cindy Sander; Yan Yin; Matthew Holtzman; Jonas Johnson; Uma N M Rao; John M Kirkwood
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more
  208 in total

Review 1.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

2.  Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer.

Authors:  Xiaowei Chen; Yoshihiro Takemoto; Huan Deng; Moritz Middelhoff; Richard A Friedman; Timothy H Chu; Michael J Churchill; Yan Ma; Karan K Nagar; Yagnesh H Tailor; Siddhartha Mukherjee; Timothy C Wang
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

Review 3.  Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer.

Authors:  Constantinos P Zambirinis; George Miller
Journal:  Trends Mol Med       Date:  2017-04-08       Impact factor: 11.951

4.  Cancer Stem Cells in the Immune Microenvironment.

Authors:  Dong-Sup Lee; Keunhee Oh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.

Authors:  Marco Bezzi; Nina Seitzer; Tomoki Ishikawa; Markus Reschke; Ming Chen; Guocan Wang; Caitlin Mitchell; Christopher Ng; Jesse Katon; Andrea Lunardi; Sabina Signoretti; John G Clohessy; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Nat Med       Date:  2018-01-08       Impact factor: 53.440

6.  Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ.

Authors:  Chang Liu; Maria Chikina; Rahul Deshpande; Ashley V Menk; Ting Wang; Tracy Tabib; Erin A Brunazzi; Kate M Vignali; Ming Sun; Donna B Stolz; Robert A Lafyatis; Wei Chen; Greg M Delgoffe; Creg J Workman; Stacy G Wendell; Dario A A Vignali
Journal:  Immunity       Date:  2019-07-23       Impact factor: 31.745

Review 7.  Energy metabolic pathways control the fate and function of myeloid immune cells.

Authors:  Amir A Al-Khami; Paulo C Rodriguez; Augusto C Ochoa
Journal:  J Leukoc Biol       Date:  2017-05-17       Impact factor: 4.962

8.  Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma.

Authors:  Laura Pinton; Samantha Solito; Elena Masetto; Marina Vettore; Stefania Canè; Alessandro Della Puppa; Susanna Mandruzzato
Journal:  Oncoimmunology       Date:  2018-03-15       Impact factor: 8.110

9.  T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Authors:  Ilaria Marigo; Serena Zilio; Giacomo Desantis; Bernhard Mlecnik; Andrielly H R Agnellini; Stefano Ugel; Maria Stella Sasso; Joseph E Qualls; Franz Kratochvill; Paola Zanovello; Barbara Molon; Carola H Ries; Valeria Runza; Sabine Hoves; Amélie M Bilocq; Gabriela Bindea; Emilia M C Mazza; Silvio Bicciato; Jérôme Galon; Peter J Murray; Vincenzo Bronte
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

10.  IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors.

Authors:  Sahil Gupta; Arpit Jain; Shahzad Nawaz Syed; Ryan G Snodgrass; Beatrice Pflüger-Müller; Matthias S Leisegang; Andreas Weigert; Ralf P Brandes; Ingo Ebersberger; Bernhard Brüne; Dmitry Namgaladze
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.